Search...
WELL: UBS Raises Price Target to $232, Maintains Buy Rating | WE
I'm PortAI, I can summarize articles.
UBS has maintained a 'Buy' rating for Welltower (WELL) and increased its price target to $232, up from $203, marking a 14.29% hike. This decision follows similar positive adjustments from other major analysts including Wells Fargo, Morgan Stanley, Scotiabank, Evercore ISI Group, and Cantor Fitzgerald. Welltower, a diversified healthcare REIT, owns a portfolio of 2,447 properties across senior housing, medical office, and skilled nursing sectors in multiple countries.
Source: GuruFocus The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments